BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Patients treated with BIMZELX® (bimekizumab-bkzx) demonstrated clinically meaningful improvements in skin pain up to 48 weeks, across various assessed outcomes At Week 16, patients treated with BIMZELX demonstrated greater draining tunnel reductions versus placebo that were sustained or…